Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Nona Biosciences Updates on ADC Collaboration with BeiGene and DualityBio

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" announced that BeiGene. Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an...

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

diseases. About Neurizon Therapeutics Limited: Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate,...

GenScript's ProBio subsidiary plays a key role in cutting-edge cancer therapies

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova...

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel...

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced that results from its Phase...

Vensica Medical raises $11M to advance Phase 2 trials for its overactive bladder treatment

in the company's goal of delivering next-generation urology treatments. About Vensica Medical: Vensica Medical is a biotechnology company focused on developing novel therapies for urological conditions. The company's leading product is a...

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

due to the potential for QT prolongation. About BioCryst Pharmaceuticals: BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases....

2nd International Conference on Biotechnology and Bioengineering 2024

2nd International Conference on Biotechnology and Bioengineering, a Hybrid Event scheduled from October 24-25, 2024, Paris, France. We cordially invite competitors from all corners of the globe to showcase their expertise, talents, and research in...

NanoMedicine International Conference 2024

NanoMedicine 2024 will cover the most recent international developments in the field of Nanobiotechnology and Nanomedicine. Participants will get a complete overview on the state of the art in these fields and on the research carried out and the...

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced that the first participant has been dosed in the Randomized Placebo Controlled Double Blind...

Blue Earth Therapeutics shares positive Phase 1 results for Lutetium (177Lu) rhPSMA-10.1 Injection, advancing its clinical development

With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start‐up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new...

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer, announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by...

Biotech Congress 2024

Biotech Congress 2024 (World Biotechnology and Bioengineering Congress) is an international conference organized by the Scholars Conferences scheduled during 23-24 September 2024 at Singapore. Biotech Congress 2024 (World Biotechnology and...

Vaxxas begins a Phase I clinical trial for an H7N9 influenza vaccine using its high-density microarray patch (HD-MAP)

central locations for vaccination, reducing the risk of further infections. About Vaxxas: Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary...

Solu Therapeutics appoints Sergio Santillana, MD, as Chief Medical Officer to strengthen its leadership team.

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment of Sergio Santillana, MD, MSc, MBA, as Chief Medical...

Stealth BioTherapeutics announces an FDA advisory committee meeting to review Elamipretide for Barth syndrome treatment

Stealth BioTherapeutics Inc. a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced that the U.S. Food and Drug...

A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe

of people all over the world. A. Menarini Diagnostics is part of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries. For more...

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Cygnus Technologies both part of Maravai LifeSciences (NASDAQ: MRVI) have collaborated to launch Cygnus’ AccuRes™ Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an...

ProJenX announces the formation of its Clinical Advisory Board

ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, announced the...

China approves the Corina Intrauterine Drug-Eluting System as a novel treatment for moderate-to-severe intrauterine adhesions (IUA)

Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who...

Results 41 - 60 of 93